Lv7
3850 积分 2022-05-24 加入
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]
2天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3天前
已完结
[Chinese expert consensus on the systemic treatment of advanced clear cell renal cell carcinoma (2024 edition)]
3天前
已完结
Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials
3天前
已完结
下肢动脉硬化闭塞症药物治疗临床研究进展
3天前
已完结
Interleukin-10 Family Cytokines Immunobiology and Structure
13天前
已完结
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
13天前
已完结
Strategies to therapeutically modulate cytokine action
13天前
已完结
Interleukin-10 in cancer immunotherapy: from bench to bedside
14天前
已完结
皖公网安备34019202002308
